{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T06:02:10Z","timestamp":1790488930331,"version":"4.1.0"},"reference-count":170,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: In recent years there has been a consistent development of clinical studies surrounding the incorporation of the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax (VEN) into the treatment of acute myeloid leukemia (AML) Methods: A search of the literature showed a tremendous development of experimental and clinical studies evaluating the impact of VEN-based regimens in the treatment of AML patients. This review comprehensively analyzes the available scientific evidence\u2014including prospective clinical trials, retrospective cohorts, and real-world studies\u2014to summarize current knowledge on the efficacy and safety of venetoclax-based regimens in AML patients. Results: Recent studies have evaluated VEN-based regimens in newly diagnosed (ND) and refractory\/relapsed (R\/R) AML patients, showing the efficacy of these treatments. VEN with hypomethylating agents (HMAs) became the standard-of-care for elderly\/unfit AML patients. Recent studies strongly support the effectiveness of VEN-based regimens in frontline treatment of adult AML patients eligible for intensive treatments. VEN-based therapies were also used in combination with targeted therapies, thus generating triplet therapeutic regimens that are under evaluation for the treatment of some AML subtypes. However, the response to VEN+HMAs is highly variable and in part depends on tumor genetics; some patients are resistant or relapse following VEN-based treatments and future studies will be required to develop therapeutic strategies able to circumvent resistance and to identify patients at high risk of relapse. Prospective randomized trials are required to establish the real efficacy of VEN in various clinical settings and to refine maintenance and discontinuation strategies, aiming to improve long-term outcomes and to make more safe treatments based on VEN.<\/jats:p>","DOI":"10.3390\/cancers18081201","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T12:21:32Z","timestamp":1775737292000},"page":"1201","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Spectrum of Venetoclax-Based Treatments in Acute Myeloid Leukemia"],"prefix":"10.3390","volume":"18","author":[{"given":"Elvira","family":"Pelosi","sequence":"first","affiliation":[{"name":"Department of Oncology, Istituto Superiore di Sanit\u00e0, Viale Regina Elena 299, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3593-1230","authenticated-orcid":false,"given":"Germana","family":"Castelli","sequence":"additional","affiliation":[{"name":"Department of Oncology, Istituto Superiore di Sanit\u00e0, Viale Regina Elena 299, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7900-8942","authenticated-orcid":false,"given":"Ugo","family":"Testa","sequence":"additional","affiliation":[{"name":"Department of Oncology, Istituto Superiore di Sanit\u00e0, Viale Regina Elena 299, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1158\/2643-3230.BCD-24-0171","article-title":"Ventoclax-based combination regimens in acute myeloid leukemia","volume":"6","author":"Goulart","year":"2025","journal-title":"Blood Cancer Discov."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood.2024024009","article-title":"How I treat patients with AML using azacitidine and venetoclax","volume":"145","author":"Wei","year":"2025","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"Dinardo","year":"2019","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/ajh.70204","article-title":"Long-term outcomes of stem cell transplant in older patients with acute myeloid leukemia treated with venetoclax-based therapies","volume":"101","author":"Pratz","year":"2026","journal-title":"Am. J. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41408-025-01263-3","article-title":"Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes in chronic myelomonocytic leukemia","volume":"15","author":"Pullarkat","year":"2025","journal-title":"Blood Cancer J."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Venditti, A., Hou, J.Z., Fenaux, P., Jonas, B.A., Vhrovac, R., Montesinos, P., Garcia, J.S., Rizzieri, D., Thirman, M.J., and Zhang, M. (Leukemia, 2026). Outcomes of patients treated with venetoclax plus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model, Leukemia, in press.","DOI":"10.52843\/cassyni.hj6yn8"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1182\/blood.2023023625","article-title":"Decitabine il older patients with AML: Quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial","volume":"144","author":"Efficace","year":"2024","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-026-06737-3","article-title":"Hypomethylating agents alone or in combination with venetoclax in very elderly acute myeloid leukemia patients: Less treatment, better care?","volume":"105","author":"Tarantini","year":"2026","journal-title":"Ann. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1158\/1078-0432.CCR-21-3405","article-title":"Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Na\u00efve Acute Myeloid Leukemia","volume":"28","author":"Konopleva","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e6885","DOI":"10.1002\/cam4.6885","article-title":"Clinical and genetic characteristics predict outcomes of acute myeloid leukemia patients with FLT3 mutations receiving venetoclax-based therapy","volume":"13","author":"Weng","year":"2024","journal-title":"Cancer Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/blood.2023021579","article-title":"Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy","volume":"143","author":"Othman","year":"2024","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1182\/bloodadvances.2022007083","article-title":"Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia","volume":"6","author":"Chua","year":"2022","journal-title":"Blood Adv."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1182\/blood-2023-185437","article-title":"Acute Myeloid Leukemia Patients Who Stopped Venetoclax or\/and Azacytidine for Other Reasons Than Progression Have a Prolonged Treatment Free Remission and Overall Survival. A Filo Study","volume":"142","author":"Garciaz","year":"2023","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Molica, M., Simio, C., De Fazio, L., Alati, C., Martino, M., and Rossi, M. (2025). Harnessing venetoclax in NPM1-mutatted AML: A path to sustained remission and beyond. Cancers, 17.","DOI":"10.3390\/cancers17233733"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2025-995","article-title":"RAS mutations negate the favorable impact of NPM1 in older patients with newly diagnosed acute myeloid leukemia treated with Ven\/HMA","volume":"146","author":"Hoff","year":"2025","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2020-140182","article-title":"Outcomes of TP53-mutant acute myeloid leuekmia with venetoclax and decitabine","volume":"136","author":"Kim","year":"2020","journal-title":"Blood"},{"key":"ref_20","first-page":"791","article-title":"Outcomes of tP53-mutant acute myeloid leukemia with decitabine and venetoclax","volume":"135","author":"Kim","year":"2020","journal-title":"Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in ilder patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-22-1183","article-title":"Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax and azacitidine","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-024-01000-2","article-title":"Comparing venetoclax in combination with hypomethylating agent-based therapies for treatment na\u00efve TP53-mutated acute myeloid leukemia: Results from the Consortium on myeloid malignancies and neoplastic diseases (COMMAND)","volume":"14","author":"Badar","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1182\/blood-2025-1705","article-title":"TP53-mutated AML and treatment outcomes in the era of hypomethylating agent\/venetoclax therapy","volume":"146","author":"Mueller","year":"2025","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1182\/blood.2024025834","article-title":"A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort","volume":"144","author":"Goldfinger","year":"2024","journal-title":"Blood"},{"key":"ref_26","first-page":"6514","article-title":"Dosing decitabine and venetoclax for terminal differentiation to improve outcomes in TP53 mutant MDS and AML","volume":"146","author":"Rockwell","year":"2025","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"7793","DOI":"10.1182\/blood-2025-7793","article-title":"The venetoclax combined with metronomic low-dose decitabine and interferon for preventing post-transplant relapse in high-risk MDS and AML patients","volume":"146","author":"Yang","year":"2025","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1182\/blood-2023-189340","article-title":"Targeting venetoclax resistance in TP53-mutated acute myeloid leukemia","volume":"142","author":"Vanttinen","year":"2023","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-21-3467","article-title":"Impact of venetoclax and azacitidine in treatment-na\u00efve patients with acute myeloid leukemia and iDH1\/2 mutations","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41408-023-00915-6","article-title":"Response patterns and impact of MRD in patients with IDH1\/2-mutated AML treated with venetoclax and hypomethylating agents","volume":"13","author":"Hammond","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/bloodadvances.2024014014","article-title":"Trial eligibility, treatment patterns, and outcome for venetoclax-based therapy in AML: A prospective cohort study","volume":"9","author":"Wolach","year":"2025","journal-title":"Blood Adv."},{"key":"ref_32","first-page":"100017","article-title":"Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS","volume":"1","author":"Othman","year":"2024","journal-title":"Blood Adv."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e435","DOI":"10.1016\/j.clml.2025.01.024","article-title":"A real-world evaluation of frontline treatment for acute myeloid leukemia with azacitidine plus venetoclax","volume":"7","author":"Brandwein","year":"2025","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00277-024-05891-w","article-title":"A systematic review of venetoclax for the treatment of unfit AML patients in real-world: Is all that glitters gold?","volume":"104","author":"Montesinos","year":"2025","journal-title":"Ann. Hematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1182\/blood-2022-169509","article-title":"ELN risk is not predictive of outcomes for treatment-na\u00efve patients with acute myeloid leukemia treated with venetoclax and azacitidine","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood.2024024944","article-title":"Genetic risk stratification and outcomes among treatment-na\u00efve patients with AML treated with venetoclax and azacitidine","volume":"144","author":"Dohner","year":"2024","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2023011757","article-title":"Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax","volume":"8","author":"Bataller","year":"2024","journal-title":"Blood Adv."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.2024025409","article-title":"Genetic risk classification for adults with AML receiving less-intensive therapies: The 2024 ELN recommendations","volume":"144","author":"Dohner","year":"2024","journal-title":"Blood"},{"key":"ref_39","first-page":"239","article-title":"Prognostic stratification in venetoclax-based acute myeloid leukemia treatments: The molecular prognostic signature tested in a real-world setting","volume":"110","author":"Ciolli","year":"2025","journal-title":"Haematologica"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1182\/bloodadvances.2024013685","article-title":"Beat-AML 2024 ELN-refined risk stratification for adults with newly diagnosed AML given lower-intensity therapy","volume":"8","author":"Hoff","year":"2024","journal-title":"Blood Adv."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1182\/blood.2024026925","article-title":"Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML","volume":"144","author":"Lachowiez","year":"2024","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Hoff, F.W., Yocum, A.O., Borate, U., Mims, A.S., Byrd, J.C., and Madanat, Y.F. (Blood Neoplasia, 2025). Beat AML genetic risk stratification model in an older VEN\/HMA-treated AML patient cohort, Blood Neoplasia, in press.","DOI":"10.1016\/j.bneo.2025.100125"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ajh.27138","article-title":"Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients","volume":"99","author":"Gangat","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/ajh.27564","article-title":"Mayo genetic risk models for newly diagnosed acute myeloid leukemia treated with venetoclax + hypomethylating agent","volume":"100","author":"Gangat","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2025-453","article-title":"Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: A multinational retrospective cohort study","volume":"146","author":"Lachowiez","year":"2025","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1182\/blood-2025-5272","article-title":"Refined genetic risk model with complex karyotype predicts outcomes of nearly diagnosed acuite myeloid leukemia treated with decitabine plus venetoclax","volume":"146","author":"Mothy","year":"2025","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3324\/haematol.2018.214882","article-title":"Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia","volume":"105","author":"Kuusanmald","year":"2020","journal-title":"Haematologica"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1182\/blood.2021011094","article-title":"Erythroid\/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia","volume":"141","author":"Kuusanmald","year":"2023","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/2159-8290.CD-22-0939","article-title":"Combinatorial BCL2 family expression in acute myeloid leukemia stem cells predicts clinical response to azacitidine\/venetoclax","volume":"13","author":"Waclawiczek","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1182\/bloodadvances.2024015734","article-title":"Prognostic significance of monocytic-like phenotype in patients with AML treated with venetoclax and azacytidine","volume":"9","author":"Zhao","year":"2025","journal-title":"Blood Adv."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1158\/2643-3230.BCD-24-0256","article-title":"Genetic and phenotypic correlates of clinical outcomes with venetoclax in acute myeloid leukemia: The GEN-PHEN-VEN study","volume":"6","author":"Lachowiez","year":"2025","journal-title":"Blood Cancer Discov."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/s41591-022-01819-x","article-title":"A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia","volume":"28","author":"Zeng","year":"2022","journal-title":"Nat. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2024-204762","article-title":"Comparing the efficacy and safety of VAC (Venetoclax, Azacitidine, Chidamide) and VA regimens as induction therapy for newly diagnosed patients with immunophenotypically mature monocytic AML","volume":"144","author":"Tan","year":"2024","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4931","DOI":"10.1007\/s00277-025-06643-0","article-title":"Efficacy and safety of venetoclax plus azacitidine based regimens in the treatment of relapsed or refractory acute myeloid leukemia: A systematic review and meta-analysis","volume":"104","author":"Cai","year":"2025","journal-title":"Ann. Hematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood-2020-137815","article-title":"Venetoclax therapy for relapsed and treatment refractory AML: Clinical outcomes and molecular predictors","volume":"136","author":"Stahl","year":"2020","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/bloodadvances.2023011106","article-title":"Ventoclax-based low intensity therapy in molecular failure of NPM1-mutated AML","volume":"8","author":"Ohtman","year":"2024","journal-title":"Blood Adv."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41408-025-01344-3","article-title":"Venetoclax and azacitidine for molecular relapse after intensive chemotherapy in NPM1 or CBF AML: A FILO study","volume":"15","author":"Orvain","year":"2025","journal-title":"Blood Cancer J."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/bloodadvances.2024013086","article-title":"Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed\/refractory AML","volume":"9","author":"Unglaub","year":"2025","journal-title":"Blood Adv."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/01.HS9.0000968948.19815.ef","article-title":"Predictors of response and outcome in patients with refractory\/relapsed acute myeloid leukemia receiving venetoclax with non-intensive chemotherapy","volume":"7","author":"Kruger","year":"2023","journal-title":"Hemasphere"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41375-024-02501-6","article-title":"A novel prognostic risk model for patients with refractory\/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents","volume":"39","author":"Shahswar","year":"2025","journal-title":"Leukemia"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1182\/blood-2025-5202","article-title":"Venetoclax, cladribine plus low-dose cytarabine for relapsed\/refractory acute myeloid leukemia: A multicenter, randomized phase II study","volume":"146","author":"Cao","year":"2015","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13045-023-01437-1","article-title":"Venetoclax combined with azacitidine and homoarringtonine in relapsed\/refractory AML: A multicenter, phase 2 trial","volume":"16","author":"Jin","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1158\/1078-0432.CCR-24-1332","article-title":"Homoharringtonine added to venetoclax and azacitidine improves outcome and mitigates genetic impact in relapsed\/refractory AML: A multicenter cohort study","volume":"31","author":"Yu","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1182\/blood-2024-201974","article-title":"Poor response of venetoclax\/azacitidine in monocytic-like acute myeloid leukemia might be associated with genetic patterns and could be improved by addition of Homoharringtonine","volume":"144","author":"Yu","year":"2024","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"100145","DOI":"10.1016\/j.bneo.2025.100145","article-title":"Omecetaxine and venetoclax in relapsed\/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1","volume":"2","author":"DiNardo","year":"2025","journal-title":"Blood Neoplasia"},{"key":"ref_67","first-page":"2864","article-title":"A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed\/refractory acute myeloid leukemia","volume":"109","author":"Murthy","year":"2024","journal-title":"Haematologica"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.1016\/j.jtct.2025.01.196","article-title":"OPutcomes with venetoclax and hypomethylating agents in relapsed acute myeloid leukemia after allogeneic hematopoietic cell transplantation: A systematic review and meta-analysis","volume":"31","author":"Shahzad","year":"2025","journal-title":"Transplant. Cell. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"6079","DOI":"10.1182\/blood-2025-6079","article-title":"Venetoclax in combination with hypomethylating agents shows promising activity in acute myeloid leukemia with late relapse post allogeneic stem cell transplant: From the EBMT acute leukemia working party","volume":"146","author":"Moukalled","year":"2025","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1182\/blood-2024-193668","article-title":"Azacitidine and venetoclax with or without lymphocyte infusion in relapsed AML post-HSCT: A single-institution retrospective study","volume":"144","author":"Peters","year":"2024","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41409-025-02723-x","article-title":"Venetoclax plus hypomethylating agents as first salvage therapy for myeloid malignancies relapsing after allogeneic HSCT","volume":"61","author":"Chiusolo","year":"2026","journal-title":"Bone Marrow Transplant."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1182\/blood.2023020102","article-title":"Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML","volume":"142","author":"Xie","year":"2023","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/bloodadvances.2021005538","article-title":"Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia","volume":"5","author":"Cherry","year":"2021","journal-title":"Blood Adv."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ajh.26061","article-title":"Venetocalx with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality","volume":"96","author":"Maiti","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Shimada, T., Takahata, A., Tanaka, K., and Toyota, S. (Int. J. Hematol., 2025). Efficacy and safety of venetoclax-based regimens versus intensive chemotherapy in older adults with newly diagnosed acute myeloid leukemia: A single-center retrospective study, Int. J. Hematol., in press.","DOI":"10.1007\/s12185-025-04111-z"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood.2024027217","article-title":"Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML","volume":"145","author":"Lu","year":"2025","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2025-6","article-title":"Results from paradigm\u2014A phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia","volume":"146","author":"Fathi","year":"2025","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1182\/blood-2025-650","article-title":"This is a title in sentence case: Venetoclax-based regimens versus intensive chemotherapy in fit older adults with newly diagnosed acute myeloid leukemia (AML): A multicenter, perspective, randomized phase II trial","volume":"146","author":"Fang","year":"2025","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41408-024-01130-7","article-title":"Venetoclax with hypomethylating agents versus intensive chemotherapy in newly diagnosed acute myeloid leukemia with myelodysplasia related changes: A propensity score-matched analysis based on International Consensus Classification","volume":"14","author":"Wan","year":"2014","journal-title":"Blood Cancer J."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1182\/bloodadvances.2024012858","article-title":"Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML","volume":"8","author":"Bewersdorf","year":"2024","journal-title":"Blood Adv."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"5952","DOI":"10.1182\/blood-2024-206400","article-title":"The well tolerated VA-based regimen bringing to high-quality of life did not absolutely inferior to intensive chemotherapy in AML patients with NPM1 mutation","volume":"144","author":"Duan","year":"2024","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"100133","DOI":"10.1016\/j.bneo.2025.100133","article-title":"Intensive chemotherapy vs venetoclax\/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML","volume":"2","author":"Zale","year":"2025","journal-title":"Blood Neoplasia"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1007\/s00277-025-06496-7","article-title":"VINCENT: A randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AML","volume":"104","author":"Kretschmer","year":"2025","journal-title":"Ann. Hematol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"108179","DOI":"10.1016\/j.leukres.2026.108179","article-title":"CPX-351 versus venetoclax plus hypomethylating agents for newly diagnosed acute myeloid leukemia: A systematic review and meta-analysis","volume":"162","author":"Miyashita","year":"2026","journal-title":"Leuk. Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1182\/blood-2025-1602","article-title":"CPX-351 versus venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia: A comparative analysis of outcomes in 600 patients","volume":"146","author":"Fathima","year":"2025","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Boussi, L., Bewersdorf, J.P., Liu, Y., Shallis, R.M., Agulme, L., Bystrom, R., Zucenka, A., Garciaz, S., DeAngelo, D., and Stone, R.M. (Haematologica, 2026). Hypomethylating agents plus venetoclax versus intensive chemotherapy in acute myelogenous leukemia with chromosome 5 and 7 abnormalities, Haematologica, in press.","DOI":"10.3324\/haematol.2025.288891"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Aguirre, L.E., Bewersdorf, J.P., Liu, Y., Shallis, R.M., Boussi, L., Zucenka, A., Garciaz, S., Bystrom, R.P., DeAngelo, D.J., and Stone, R.M. (Blood Neoplasia, 2026). Comparative effectiveness of HMA plus venetoclax versus intensive chemotherapy in AML with very-high-risk cytogenetics, Blood Neoplasia, in press.","DOI":"10.1016\/j.bneo.2026.100201"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1182\/blood-2023-188400","article-title":"First line venetoclax and a hypomethylating agent or conventional chemotherapy in older adults with IDH-mutated AML","volume":"142","author":"Bouligny","year":"2023","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1002\/ajh.27366","article-title":"Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia- A multicenter cohort study","volume":"99","author":"Bewersdorf","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"S464","DOI":"10.1016\/S2152-2650(25)01738-0","article-title":"AML 851: Real-world comparison of hypomethylating agent-venetoclax and intensive chemotherapy in elderly acute myeloid leukemia: Survival and safety insights from a global matched cohort","volume":"25","author":"Khan","year":"2025","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41408-025-01363-0","article-title":"Genotype-guided comparison of VEN\/HMA versus intensive chemotherapy in newly diagnosed intermediate-risk AML: A multicenter real-world study","volume":"15","author":"Chen","year":"2025","journal-title":"Blood Cancer J."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/ajh.26991","article-title":"Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia","volume":"98","author":"Matthews","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"6996","DOI":"10.1182\/blood-2025-6996","article-title":"Real-world outcomes of venetoclax-based therapy vs intensive chemotherapy in older adults with newly diagnosed acute myeloid leukemia","volume":"146","author":"Moghaddam","year":"2025","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: Results from a phase Ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: A phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1182\/blood.2022016963","article-title":"Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"6073","DOI":"10.1182\/blood-2024-208801","article-title":"The efficacy of LDAC+Venetoclax and CPX-351 over traditional regimen in older patients with AML not eligible for intensive therapy: A meta-analysis and systematic review","volume":"144","author":"Wang","year":"2024","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Wei, A.H., Panayotidis, P., Montesinos, P., Ivanov, V., DiNardo, C.D., Novak, J., Laribi, K., Kim, I., Stevens, D.A., and Fiedler, W. (Blood Adv., 2026). Risk stratification at low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy, Blood Adv., in press.","DOI":"10.1182\/bloodadvances.2025017083"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/bjh.18788","article-title":"Venetoclax plus azacitidine and LDAC induced high response rates in acute myelkoid leukemia in routine clinical practice","volume":"201","author":"Liu","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1182\/blood-2024-206513","article-title":"Venetoclax, Azacitidine, combined with low-dose cytarabine in older newly diagnosed acute myeloid leukemia: The result of a prospective, multicenter, open, randomized controlled trials","volume":"144","author":"Han","year":"2024","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"6197","DOI":"10.1007\/s00277-025-06653-y","article-title":"Safety and efficacy of venetoclax-azacitidine combined with low-dose idarubicin and cytarabine regimens for the treatment of newly diagnosed acute myeloid leukemia patients compared to the standard chemotherapy: A propensity score-matched real-world single-center experience","volume":"104","author":"Chen","year":"2025","journal-title":"Ann. Hematol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1016\/S2352-3026(22)00106-5","article-title":"Venetoclax plus 3+7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukemia: A multicentre, single-arm, phase 2 trial","volume":"9","author":"Wang","year":"2022","journal-title":"Lancet Hematol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e3260","DOI":"10.1002\/hon.3260","article-title":"Venetoclax plus daunorubicin and cytarabine in newly diagnosed acute myeloid leukemia patients: A propensity score-matched analysis","volume":"42","author":"Wang","year":"2024","journal-title":"Hematol. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood.2024026700","article-title":"Venetoclax plus daunorubicin and cytarabine for newly diagnosed acute myeloid leukemia: Results of a phase 1b study","volume":"145","author":"Mantzaris","year":"2025","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1182\/blood-2024-203422","article-title":"Venetoclax combined with intensive chemotherapy as an induction chemotherapy in newly diagnosed FLT3-ITD-positive AML","volume":"144","author":"Liu","year":"2024","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/bloodadvances.2024014900","article-title":"Final analysis of the phase 1b chemotherapy and venetoclax in elderly acute myeloid leukemia trial (CAVEAT)","volume":"9","author":"Chua","year":"2025","journal-title":"Blood Adv."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/s41375-025-02531-8","article-title":"Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2025","journal-title":"Leukemia"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1182\/blood-2024-209476","article-title":"FLAG-IDA in high-risk newly diagnosed and relapsed or refractory acute myeloid leukemia: The Pricess Margaret Cancer Center experience","volume":"144","author":"Davidson","year":"2024","journal-title":"Blood"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"6519","DOI":"10.1200\/JCO.2024.42.16_suppl.6519","article-title":"FLAG-IDA + venetoclax in newly diagnosed (ND) or relapsed\/refractory (RR) AML","volume":"42","author":"Jen","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/ejh.14302","article-title":"Venetoclax combined with FLAG-IDA in refractory or relapsed acute myeloid leukemia","volume":"114","author":"Wille","year":"2025","journal-title":"Eur. J. Haematol."},{"key":"ref_112","first-page":"72","article-title":"Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed\/refractory acute myeloid leukemia","volume":"109","author":"Shahswar","year":"2024","journal-title":"Haematologica"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1182\/blood.2025029391","article-title":"FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML","volume":"146","author":"Raj","year":"2025","journal-title":"Blood"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood-2025-1666","article-title":"High remission rates with FLAG-IDA-venetoclax in acute myeloid leukemia: \u201cLess is more\u201d on days of venetoclax in the intensive regimen","volume":"146","author":"Fedorov","year":"2025","journal-title":"Blood"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2024-209199","article-title":"Comparison of FLAG-idarubicin to FLAG-idarubicin plus venetoclax for treatment of newly diagnosed AML in patients eligible for intensive induction. Analysis of 200 consecutive patients treated as a single center","volume":"144","author":"Bashey","year":"2024","journal-title":"Blood"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Schonrock, M., Sonnemann, P., Michalowski, P., Heuser, M., Thol, F., Ayuk, F.A., Wolschke, C., Klyucnikov, E., Bokemeyer, C., and Fiedler, W. (2024). Dose-reduced FLA-IDA in combination with venetoclax is an effective and safe salvage therapy in relapsed and refractory acute myeloid leukemia (R\/R AML). Cancers, 16.","DOI":"10.3390\/cancers16223872"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1182\/bloodadvances.2024014901","article-title":"Safety run-in and part 1 of GIMEMA AML1718: Venetoclax combined with FLAI as induction treatment in non-low-risk AML","volume":"9","author":"Marconi","year":"2025","journal-title":"Blood Adv."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(25)00358-8","article-title":"Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukemia (RELAX): A multicentre, single-arm, phase 1\u20132 trial","volume":"13","author":"Ruhnke","year":"2026","journal-title":"Lancet Hemtol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1016\/S2352-3026(21)00192-7","article-title":"Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome: A cohort from a single-centre, single-arm, phase 1 trial","volume":"8","author":"Kadia","year":"2021","journal-title":"Lancet Hematol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"6962","DOI":"10.1182\/blood-2025-6962","article-title":"Clia plus venetoclax for AML: Feasibility and efficacy to a hybrid community setting","volume":"146","author":"Bambace","year":"2025","journal-title":"Blood"},{"key":"ref_121","unstructured":"Lee, B.J., Griffin, S., Doh, J., Quach, A., Sun, Y., Chamnusiriwath, P., Ciurea, S.O., Ramos-Perez, J., Bellman, P., and Jeyakumar, P.M. (Br. J. Haematol., 2026). Venetoclax combined with cladribine, idarubicin, cytarabine (CLIA-VEN) results in higher remission rates over conventional 7+3 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukemia, Br. J. Haematol., in press."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e70214","DOI":"10.1002\/hem3.70214","article-title":"A phase 2 study of CPX-351 in combination with venetoclax in patients with newly diagnosed high-risk acute myeloid leukemia","volume":"9","author":"Jen","year":"2025","journal-title":"HemaSphere"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1038\/s41375-025-02733-0","article-title":"Outcomes of adult patients with newly diagnosed IDH-mutated AML treated with intensive chemotherapy and venetoclax","volume":"39","author":"Croden","year":"2025","journal-title":"Leukemia"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission","volume":"383","author":"Wei","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1182\/blood.2022016293","article-title":"Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azicitidine","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"E84","DOI":"10.1002\/ajh.26847","article-title":"Long-term survival with oral azacitidine after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial","volume":"98","author":"Wei","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1182\/bloodadvances.2020002544","article-title":"A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients","volume":"4","author":"Oran","year":"2020","journal-title":"Blood Adv."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"e287","DOI":"10.1016\/S2352-3026(24)00034-6","article-title":"reduced-dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukemia following intensive or low-intensity induction: Results of a single-centre phase 2 trial","volume":"11","author":"Bazinet","year":"2024","journal-title":"Lancet Hematol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"6960","DOI":"10.1182\/blood-2025-6960","article-title":"Maintenance with hypomethylating agent+ venetoclax after intensive induction chemotherapy in patients with newly diagnosed acute myeloid leukemia","volume":"146","author":"Medawar","year":"2025","journal-title":"Blood"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/s41409-023-01987-5","article-title":"Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse","volume":"58","author":"Kent","year":"2023","journal-title":"Bone Marrow Transplant."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1182\/blood-2025-2511","article-title":"Phase II rtial of venetoclax in combination with azacitidine as maintenance therapy for high-risk acute leukemia following allogeneic stem cell transplantation","volume":"146","author":"Oran","year":"2025","journal-title":"Blood"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1182\/bloodadvances.2023012120","article-title":"Prophylactic maintenance with venetoclax\/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML","volume":"8","author":"Garcia","year":"2024","journal-title":"Blood Adv."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood-2025-4261","article-title":"Improved outcomes with low-dose hypomethylating agent plus venetoclax as post-transplant maintenance in patients undergoing reduced intensity conditioning allogeneic hematopoietic stem cell transplantation for myeloid malignancies","volume":"146","author":"Diebold","year":"2025","journal-title":"Blood"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1182\/blood.2021014586","article-title":"Phase 3 trial of gilteritinib plus axacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy","volume":"140","author":"Wang","year":"2022","journal-title":"Blood"},{"key":"ref_135","first-page":"1034","article-title":"Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia","volume":"106","author":"Mai","year":"2021","journal-title":"Haematologica"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1182\/blood.2021014241","article-title":"Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1","volume":"140","author":"Janseen","year":"2002","journal-title":"Blood"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1200\/JCO.22.00602","article-title":"Venetoclax plus gilteritinib for FLT3-mutated relapsed\/refractory acute myeloid leukemiua","volume":"40","author":"Daver","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41408-021-00410-w","article-title":"Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia","volume":"11","author":"Maiti","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41408-022-00670-0","article-title":"Hypomethylating agent and venetoclax with FLT3 inhibitor triplet therapy in older\/unfit patients with FLT3 mutated AML","volume":"12","author":"Yilmaz","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41408-023-00911-w","article-title":"Treatment of older adults with FLT3-mutated AML: Emerging paradigma and the role of frontline FLRT3 inhibitors","volume":"13","author":"Short","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1200\/JCO.23.01911","article-title":"Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML","volume":"42","author":"Short","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2025-45","article-title":"Long-term follow-up of azacitidine, venetoclax, and gilteritinib in patients with newly diagnosed FLT3-mutated acute myeloid leukemia","volume":"146","author":"Azevedo","year":"2025","journal-title":"Blood"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1182\/blood-2025-654","article-title":"Venetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed (ND) FLT3mut+ acute myeloid leukemia (AML) ineligible for intensive chemotherapy (chemo): Interim results from the phase 1\u20132 VICEROY study","volume":"146","author":"Altman","year":"2025","journal-title":"Blood"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"5226","DOI":"10.1182\/blood-2025-5226","article-title":"A phase II study of azacitidine, venetoclax, and gilteritinib for newly diagnosed adverse risk FLT3-wild type acute myeloid leukemia","volume":"146","author":"Arora","year":"2025","journal-title":"Blood"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1182\/blood-2025-2519","article-title":"Efficacy of the triplet tehrapy with venetoclax, azacitidine and gilteritinib for the treatment of FLT3-ITD-mutated AML patients with relapsed\/refractory disease or persistent minimal residual disease bridging to allogeneic hematopoietic stem cell transplantation","volume":"146","author":"Jiang","year":"2025","journal-title":"Blood"},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Short, N.J., Loghavi, S., Yilmaz, M., Karrar, O., Kim, K., DiNardo, C.D., Kadia, T.M., Maround, M., Borthakur, G., and Issa, G.C. (Haematologica, 2026). Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor, Haematologica, in press.","DOI":"10.3324\/haematol.2025.288553"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1002\/ajh.70053","article-title":"Cytomolecular mechanisms of relapse and post-relapse outcomes after frontline FLT3 inhibitor-based therapy in FLT3-mutated AML","volume":"100","author":"Arora","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"S460","DOI":"10.1016\/S2152-2650(25)01730-6","article-title":"AML-804: Triplet therapy with decitabine, venetoclax, and quizartinib for FLT3-ITD mutated AML: A phase 1\u20132 study","volume":"25","author":"Yilmaz","year":"2025","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_149","first-page":"217","article-title":"A phase II randomized trial comparing low-dose cytarabine and venetoclax +\/- midostaurin in non-adverse cytogenetic risk acute myeloid leukemia: The ALLG AMLM25 intervene trial","volume":"146","author":"Chua","year":"2025","journal-title":"Blood"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.1182\/bloodadvances.2025016399","article-title":"Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML","volume":"9","author":"Montesinos","year":"2025","journal-title":"Blood Adv."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1200\/JCO-25-00640","article-title":"Outcomes of frontline triplet regimens with a hypomethylating agent, venetoclax, and isocitrate dehydrogenase inhibitor for intensive chemotherapy-ineligible patients with isocitrate dehydrogenase-mutated AML","volume":"43","author":"DiNardo","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_152","first-page":"68","article-title":"Reply to: Late non-relapse mortality: A hidden risk in triplet therapy for IDH-mutated AML?","volume":"44","author":"DiNardo","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"S404","DOI":"10.1016\/S2152-2650(25)01629-5","article-title":"AML-150: A phase 1b\/2 trial of an all-oral triplet regimen for IDH-mutated myeloid malignancies: Decitabine or cedazuridine and venetoclax in combination with ivosidenib or enasidenib","volume":"25","author":"Maiti","year":"2025","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1038\/s41467-021-22874-x","article-title":"Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitorsa in acute myeloid leukemia","volume":"12","author":"Wang","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1158\/2643-3230.BCD-22-0205","article-title":"A phase Ib\/II study of ivosidenib with venetoclax \u00b1 azacitidine in IDH1-mutated myeloid malignancies","volume":"4","author":"Lachowiez","year":"2023","journal-title":"Blood Cancer Discov."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.stem.2025.04.012","article-title":"Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia","volume":"32","author":"Sirenko","year":"2025","journal-title":"Cell Stem Cell"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1182\/blood.2024027948","article-title":"Rapid clonal selection within early hematopoietic cell compartment presages the outcome of ivosidenib combination therapy","volume":"147","author":"Turkalji","year":"2026","journal-title":"Blood"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/sj.leu.2403224","article-title":"Interleukin-3 receptor in acute leukemia","volume":"18","author":"Testa","year":"2004","journal-title":"Leukemia"},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Pelosi, E., Castelli, G., and Testa, U. (2023). CD123 a therapeutic target for acute myeloid leukemia and blastic plasmocytoid dendritic neoplasm. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032718"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood-2002-03-0852","article-title":"Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity and poor prognosis","volume":"100","author":"Testa","year":"2002","journal-title":"Blood"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1365-2141.2008.07491.x","article-title":"Interleukin (IL)-3\/granulocyte macrophage-colony stimulating factor \/IL-5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukemias with mutated FMS-related tyrosine 3 kinase receptor","volume":"144","author":"Riccioni","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1365-2141.2011.08577.x","article-title":"Immunophenotypic features of acute myeloid leukemia patients exhibiting high Flt3 expression not associated with mutations","volume":"153","author":"Riccioni","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Perriello, V.M., Gionfriddo, I., Rossi, R., Milano, F., Mezzasoma, F., Marra, A., Spinelli, O., Rambaldi, A., Annibali, O., and Avvisati, G. (2021). CD123 is consistently expressed on NPM1-mutated AML cells. Cancers, 13.","DOI":"10.3390\/cancers13030496"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"4155","DOI":"10.1182\/blood-2023-187018","article-title":"Venetoclax synergizes with IMGN632, a novel CD123 targeting antibody conjugated to a DNA alkylating payload, by suppressing DNA damage response and potentiating apoptosis in acute myeloid leukemia in vitro models","volume":"142","author":"Skwarska","year":"2023","journal-title":"Blood"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"6104","DOI":"10.1182\/blood-2024-205837","article-title":"Prognostic significance of CD123 expression in acute myeloid leukemia treated with venetoclax and hypomethylating agents","volume":"144","author":"Tiu","year":"2024","journal-title":"Blood"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1182\/blood-2023-173413","article-title":"Pivekimab surinine (PVEK, IMGN632), a CD123-targeting antibody-drug conjugate, in combination with azacitidineand venetoclax in patients with newly diagnosed acute myeloid leukemia","volume":"142","author":"Daver","year":"2023","journal-title":"Blood"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1182\/blood-2025-651","article-title":"Efficacy and safety of pevikimab sunirine in combination with venetoclax plus azacitidine in unfit patients with newly diagnosed acute myeloid leukemia","volume":"146","author":"Daver","year":"2025","journal-title":"Blood"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1182\/blood-2025-5195","article-title":"Efficacy and safety of pivekimab sunirine in blastic plasmocytoid dendritic cell neoplasm in patients with prior or concomitant hematologic malignancy; results from the cadenza study","volume":"146","author":"Pemmaraju","year":"2025","journal-title":"Blood"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1182\/blood-2025-653","article-title":"Tagroxofusp, azacitidine and venetoclax (TAG-AZA-VEN) triplet therapy shows efficacy, tolerability, and transplant potential in patients with blastic plasmocytoid dendritic cell neoplasm (BPDCN): Results of a phase 2 trial","volume":"146","author":"Lane","year":"2025","journal-title":"Blood"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1182\/blood-2025-5198","article-title":"A dose optimization phase 1b\/2 study evaluating mipletamig (formerly APVO436), a novel bispecific CD123 \u00d7 CD3 ADAPTIRO\u2019 molecule in combination therapy for the treatment of frontline acute myeloid leukemia (AML) in patients unfit for intensive chemotherapy","volume":"146","author":"Watts","year":"2025","journal-title":"Blood"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/8\/1201\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T08:02:33Z","timestamp":1776412953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/8\/1201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":170,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["cancers18081201"],"URL":"https:\/\/doi.org\/10.3390\/cancers18081201","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]}}}